Skip to content

Study · Randomized controlled trial · n = 9,340 · 2020

4 results

The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.

Leiter LA, Bain SC, Bhatt DL, Buse JB, Mazer CD, Pratley RE, Rasmussen S, Ripa MS, Vrazic H, Verma S

Diabetes, obesity & metabolism3 Jun 2020Cited by 29 (Europe PMC)

PMID32372454 (opens in a new tab)PMCIDPMC7496251 (opens in a new tab)DOI10.1111/dom.14079 (opens in a new tab)PepBankPUB-32372454
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes at high cardiovascular risk (LEADER), the effect of liraglutide on MACE showed no significant heterogeneity across baseline blood pressure categories.

    In plain wordsIn adults with type 2 diabetes, liraglutide's effect on heart events compared with placebo did not differ clearly across blood pressure groups.

    Peptide
    Liraglutide
    Outcome
    No significant changeMACE effect heterogeneity across baseline BP categories
    Study

    n = 9,340

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was no statistical heterogeneity across the BP categories for the effects of liraglutide (P = .06 for MACE; P = .14 for nephropathy) or semaglutide (P = .40 for MACE; P = .27 for nephropathy) versus placebo.
    1 context sentence
    Summary · context
    Using data from the LEADER (9340 patients) and SUSTAIN 6 (3297 patients) trials, we evaluated post hoc the cardiorenal effect of liraglutide and semaglutide on major adverse cardiovascular events (MACE) and nephropathy by baseline BP categories using a Cox proportional hazards model (treatment and s…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes at high cardiovascular risk (LEADER), the effect of liraglutide on nephropathy showed no significant heterogeneity across baseline blood pressure categories.

    In plain wordsIn adults with type 2 diabetes, liraglutide's effect on kidney disease compared with placebo did not differ clearly across blood pressure groups.

    Peptide
    Liraglutide
    Outcome
    No significant changeNephropathy effect heterogeneity across baseline BP categories
    Study

    n = 9,340

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was no statistical heterogeneity across the BP categories for the effects of liraglutide (P = .06 for MACE; P = .14 for nephropathy) or semaglutide (P = .40 for MACE; P = .27 for nephropathy) versus placebo.
    1 context sentence
    Summary · context
    Using data from the LEADER (9340 patients) and SUSTAIN 6 (3297 patients) trials, we evaluated post hoc the cardiorenal effect of liraglutide and semaglutide on major adverse cardiovascular events (MACE) and nephropathy by baseline BP categories using a Cox proportional hazards model (treatment and s…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes at high cardiovascular risk (SUSTAIN 6), the effect of semaglutide on MACE showed no significant heterogeneity across baseline blood pressure categories.

    In plain wordsIn adults with type 2 diabetes, semaglutide's effect on heart events compared with placebo did not differ clearly across blood pressure groups.

    Peptide
    Semaglutide
    Outcome
    No significant changeMACE effect heterogeneity across baseline BP categories
    Study

    n = 3,297

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was no statistical heterogeneity across the BP categories for the effects of liraglutide (P = .06 for MACE; P = .14 for nephropathy) or semaglutide (P = .40 for MACE; P = .27 for nephropathy) versus placebo.
    1 context sentence
    Summary · context
    Using data from the LEADER (9340 patients) and SUSTAIN 6 (3297 patients) trials, we evaluated post hoc the cardiorenal effect of liraglutide and semaglutide on major adverse cardiovascular events (MACE) and nephropathy by baseline BP categories using a Cox proportional hazards model (treatment and s…
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes at high cardiovascular risk (SUSTAIN 6), the effect of semaglutide on nephropathy showed no significant heterogeneity across baseline blood pressure categories.

    In plain wordsIn adults with type 2 diabetes, semaglutide's effect on kidney disease compared with placebo did not differ clearly across blood pressure groups.

    Peptide
    Semaglutide
    Outcome
    No significant changeNephropathy effect heterogeneity across baseline BP categories
    Study

    n = 3,297

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was no statistical heterogeneity across the BP categories for the effects of liraglutide (P = .06 for MACE; P = .14 for nephropathy) or semaglutide (P = .40 for MACE; P = .27 for nephropathy) versus placebo.
    1 context sentence
    Summary · context
    Using data from the LEADER (9340 patients) and SUSTAIN 6 (3297 patients) trials, we evaluated post hoc the cardiorenal effect of liraglutide and semaglutide on major adverse cardiovascular events (MACE) and nephropathy by baseline BP categories using a Cox proportional hazards model (treatment and s…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 3 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT05535322

Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity

Ana Palancan = 26,9441 Jan 2014 to 1 Sept 2022

Type 2 Diabetes · Obesity

Trial pageClinicalTrials.govUpdated 28 Sept 2022
CompletedPhase 3Results postedNCT01720446

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 3,29721 Feb 2013 to 15 Mar 2016

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 27 Jun 2019
CompletedPhase 3Results postedNCT01179048

Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Novo Nordisk A/Sn = 9,34131 Aug 2010 to 17 Dec 2015

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 17 Jul 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.